Paclitaxel oral - DAE HWA Pharmaceutical

Drug Profile

Paclitaxel oral - DAE HWA Pharmaceutical

Alternative Names: DHP107; Liporaxel

Latest Information Update: 31 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DAE HWA Pharmaceutical
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Gastric cancer

Most Recent Events

  • 02 Nov 2017 DAE HWA Pharmaceutical plans the phase II OPERA trial for Breast cancer (Recurrent, Metastatic disease, Second-line therapy or greater) in USA in December 2017 (NCT03326102)
  • 25 Oct 2017 DAE HWA Pharmaceutical plans the phase II/III OPTIMAL trial for Breast cancer (Recurrent, Metastatic disease, First-line therapy) in South Korea in November 2017 (NCT03315364)
  • 31 May 2016 Preregistration for Gastric cancer (Late-stage disease, Second-line therapy or greater) in South Korea (PO) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top